Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor–Mutated Non-Small Cell Lung Cancer Patients

Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters

(2018) Chihiro Endo-Tsukude et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation

(2018) Dehua Liao et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Polymorphism of CYP1A1 gene variants rs4646903 and rs1048943 relation to the incidence of cervical cancer in Chhattisgarh

(2017) Vijaylakshmi Jain et al.   ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY

CYP1A1*2A polymorphism as a prognostic factor for the advanced lung cancer patients treated with EGFR-TKI and its correlation with EGFR mutation.

(2017) Q. Nie et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) S. Novello et al.   ANNALS OF ONCOLOGY

Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products

(2016) Gail D. Anderson et al.   CLINICAL PHARMACOKINETICS

Strategies to Inhibit ABCB1- and ABCG2-Mediated Efflux Transport of Erlotinib at the Blood–Brain Barrier: A PET Study on Nonhuman Primates

(2016) Nicolas Tournier et al.   JOURNAL OF NUCLEAR MEDICINE

Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters

(2016) Y Ma et al.   PHARMACOGENOMICS JOURNAL

Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors

(2016) Claudia Neul et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Therapeutic drug monitoring of targeted anticancer therapy

(2015) Laurent A Decosterd et al.   Biomarkers in Medicine

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer

(2015) Lonneke Timmers et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions

(2013) J. F. Gainor et al.   ONCOLOGIST

Plasma Concentrations of Tyrosine Kinase Inhibitors Imatinib, Erlotinib, and Sunitinib in Routine Clinical Outpatient Cancer Care

(2013) Nienke A. G. Lankheet et al.   THERAPEUTIC DRUG MONITORING

Association ofABCB1polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer

(2012) Akinobu Hamada et al.   PHARMACOGENOMICS

CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism

(2011) Qiang Nie et al.   EUROPEAN JOURNAL OF CANCER

Personalizing medicine with clinical pharmacogenetics

(2011) Stuart A. Scott   GENETICS IN MEDICINE

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers

(2009) Andrew N. Hughes et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacogenomic and Pharmacokinetic Determinants of Erlotinib Toxicity

(2008) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

(2008) S. Marchetti et al.   MOLECULAR CANCER THERAPEUTICS